Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue's opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe. The company has a strategic connectivity and licensing agreement with Masimo that grants Senzime the rights to use some of Masimo's intellectual property; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.
Часто задаваемые вопросы
В каком секторе работает Senzime AB (publ) (SNZZF)?
Senzime AB (publ) относится к сектору Здравоохранение.
Какова текущая цена акций Senzime AB (publ) (SNZZF)?
По последним данным, цена акций Senzime AB (publ) составляет 0,24 $, предыдущее закрытие — 0,24 $.
Выплачивает ли Senzime AB (publ) (SNZZF) дивиденды?
Нет, Senzime AB (publ) не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Senzime AB (publ) (SNZZF)?
У компании Senzime AB (publ) бета 0.428, что указывает на более низкую волатильность по сравнению с рынком в целом.
